MV BioTherapeutics participated for the first time to the international event Bio Digital 2020 presenting the company, the pipeline to over 50 companies.
“We weren’t sure about the potential success when we applied to the Swiss Pavillon with the sponsoring of Innosuisse” confirms Dr. Fabio Grassi, founder and chairman. “The support we got from Switzerland Global Enterprise team prior to the meetings was really outstanding”.
The 30 minutes meeting held were with very different companies. We met potential licensing partners for both our pharma and animal health application.
Also an important contribution from CMOs and CROs that will be needed in the future moving forward into clinics. And last but no least some potential investors.
The meetings confirmed that our Cancer Immunotherapy enhancer candidate (MV-002), with the latest enthusiastic results obtained, is getting the largest attention and interest.
There are some discussions ongoing and our participation to the Bio Digital 2020 motivated us even more confirming that we are on the right track.
About MV BioTherapeutics
MV BioTherapeutics was founded in 2018 as a spin-off from the Institute for Research in Biomedicine (IRB) in Bellinzona.
The patent protected Apy platform is a unique mechanism to generate protective immune response against enteric infections.
It shapes the intestinal microbiota in medical conditions with two applications:
is a technology platform for live attenuated oral vaccines eliciting protective mucosal responses against enteric pathogens.
The first application is a vaccine for Clostridioides difficile infection. This is a disease that is causing hundreds of thousands of casualties every year and generating huge medical costs.
is a live biotherapeutic that has been validated in pre-clinical studies. It is an enhancer of immune checkpoint blockade in cancer immunotherapy and as a modulator of antibiotic-induced dysbiosis.
Research experiments and preclinical trials are performed in the research lab hosted at IRB.
The company is looking for seed funding or strategic partnerships in order to move forward as a fully operational company into clinics.